Surface Oncology

New immunotherapies represent one of the most significant breakthroughs in recent decades for people with cancer, validating the long-sought goal of re-awakening the immune system to recognize and destroy cancer cells. But this first wave of new immunotherapies, checkpoint inhibitors, is not enough. Checkpoint inhibitors are limited in the types of cancer they treat, the overall number of patients who benefit, and for many patients, the depth and duration of response.

The initial narrow focus on checkpoint inhibition fails to address the multitude of additional processes known to play a role in enabling cancer cells to escape immune detection and eradication, ultimately limiting these therapies’ impact and reach.